Here is IP Think Tank’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

India: Rejections from pre-grant appealable to IPAB by patent applicant: UCB Farchim SA v Cipla & Ors (Generic Pharmaceuticals and IP) (The Vanishing Point) (Indian Patent Oppositions) (Spicy IP) (Spicy IP)

India: Nay patent linkages: Bayer v UOI upheld by Division Bench of Delhi High Court (Spicy IP) (Generic Pharmaceuticals and IP)

US: SACGHS final report on gene patents meets opposition from BIO (Patents4Life) (Patents4Life) (Patent Docs)

Neutrokine-α – UK: EWCA dismisses Human Genome Sciences appeal against decision finding  invalidity; invention not ‘susceptible of industrial application’: Eli Lilly v Human Genome Sciences Inc (EPLAW) (IPKat)

GSK announces ‘open innovation’ strategy to combat neglected tropical diseases (Patent Docs)

Who quizzes WHO’s role in solving the Influenza pandemic crisis: An Insight (IP Osgoode)

Canada: Patenting higher life forms in Canada: Resistance and contradictions: Harvard College v. Canada (Commissioner of Patents); Monsanto Canada Inc. v. Schmeiser (IP Osgoode)

Canada: Doctrine of sound prediction and the case of Apotex Inc v Wellcome Foundation Ltd (IP Osgoode)

Chile Industrial Association of Pharmaceutical Laboratories (Asilfa) responds to the American Chamber of Commerce allegations of copying certain American laboratories medicines (IP tango)

China: Higher People’s Court of Beijing recognizes novelty in dosage limitations in Swiss-Form claims (Patents4Life)

EU: EPO: More about Alice – Pelargonium extract patent challenge (Afro-IP)

Haiti: The Haitian plight and traditional knowledge: A promise unfulfilled? – Crofelemer treatment for dehydration (Spicy IP)

India: Nay patent linkages: Bayer v UOI upheld by Division Bench of Delhi High Court (Spicy IP) (Generic Pharmaceuticals and IP)

India: Rejections from pre-grant appealable to IPAB by patent applicant: UCB Farchim SA v Cipla & Ors (Generic Pharmaceuticals and IP) (The Vanishing Point) (Indian Patent Oppositions) (Spicy IP) (Spicy IP)

India: Buckuchurbu and (re) hydrating indian traditional knowledge (Spicy IP)

Peru: Maize as cultural heritage (IP Osgoode)

US: SACGHS final report on gene patents meets opposition from BIO (Patents4Life) (Patents4Life) (Patent Docs)

US: Newsweek = Newspeak on gene patenting (Patent Docs)

US: Letter to Congressional Leaders seeks patent protections (Patent Docs)

US: Novartis files for review and correction of the patent term adjustment calculation in respect of patent covering ‘Coumarins useful as biomarkers’: Novartis AG v. Kappos (Patent Docs)

US: Recent rulings once again shine light on sham citizen petition antitrust issues (FDA Law Blog)

US: Celsis files patent infringement suit based on defendants’ manufacture and sale of hepatocyte products including CryoXTreme: Celsis In Vitro, Inc. v. Xenotech, LLC et al. (Patent Docs)

US: Boram files patent infringement suit against Life Technologies based on manufacture and sale of BaculoDirect Baculovirus Expression System (Patent Docs)

US: Fate Therapeutics to Receive First U.S. Patent for Induced Pluripotent Stem Cell Technology (Patent Docs)

Actos (Pioglitazone) –US:Patent infringement complaint filed following a Paragraph IV certification: Takeda Pharmaceutical Co. et al. v. Aurobindo Pharma Ltd. et al. (Patent Docs)

Aldara (Imiquimod) – US: FDA denies Graceway petition on generic Aldara cream (FDA Law Blog)

Brovana (Arformoterol) – US: Sepracor files patent infringement suit against Teva in response to Para IV challenge (Patent Docs)

Caduet (Amlodipine, atorvastatin) – US: Patent infringement complaint in response to ANDA filing: Pfizer Inc. et al. v. Mylan Pharmaceuticals Inc. (Patent Docs)

Colmetec (Olmesartan medoxomil, hydrochlorothiazide) – France: Cour d’appel de Paris say ‘non’ to olmesartan medoxomil and hydrochlorothiazide combination SPC: Daiichi Sankyo Company v INPI (SPC Blog)

Crestor (Rosuvastatin) – US: Generic drug makers, Teva, Apotex and others seek to remove AstraZeneca LP as party in Crestor suit (Patent Docs)

Differin (Adapalene) – US: Patent infringement complaint following a Paragraph IV certification – Galderma Laboratories LP et al. v. Tolmar Inc. (Patent Docs)

Doryx (Doxycycline) – US: Warner Chilcott files patent infringement suit against Sandoz in response to Para IV challenge (Patent Docs)

Ebixa (Memantine) – Canada: Duty of good faith patent prosecution: Lundbeck v Ratiopharm (IP Osgoode)

Focalin (Dexmethylphenidate) – US: Settlement announced in Focalin infringement dispute involving Celgene, Novartis Pharmaceuticals and Teva Pharmaceuticals (Patent Docs)

Gemzar (Gemcitabine) – US: Patent infringement complaint filed in S D Indiana following a Paragraph IV certification – Eli Lilly and Company v. Fresenius Kabi Oncology PLC (Patent Docs)

Neutrokine-α – UK: EWCA dismisses Human Genome Sciences appeal against decision finding invalidity; invention not ‘susceptible of industrial application’: Eli Lilly v Human Genome Sciences Inc (EPLAW) (IPKat)

Nuvigil (Armodafinil) – US: Patent infringement complaints filed in Colorado and Delaware following a Paragraph IV certification as part of Sandoz’s filing of an ANDA to manufacture a generic version of Cephalon’s Nuvigil: Cephalon, Inc. et al. v. Sandoz Inc. (Patent Docs)

Opana (Oxymorphone) – US: Endo files patent infringement suit against Roxane in response to Para IV challenge (Patent Docs)

Ortho Tri-Cyclen Lo (Ethinyl estradiol, norgestimate) – US:Patent infringement complaint filed in New Jersey following a Paragraph IV certification: Ortho-McNeil-Janssen Pharmaceuticals, Inc. v. Lupin Pharmaceuticals, Inc. et al. (Patent Docs)

Pataday (Olopatadine hydrochloride ophthalmic solution) – US: Patent infringement complaint filed in S D Indiana following a Paragraph IV certification: Alcon Research, Ltd. et al. v. Sandoz Inc. (Patent Docs)

Ryzolt (Tramadol) – US: Patent infringement complaint filed following a Paragraph IV certification: Purdue Pharma Products LP et al. v. Anchen Pharmaceuticals Inc. (Patent Docs)

Seasonique (Levonorgestrel, ethinyl estradiol) – US: Teva files patent infringement suit against Lupin in response to Para IV challenge (Patent Docs)

Simcor (Simvastatin, niacin) – US: Patent infringement complaint filed following a Paragraph IV certification: Abbott Laboratories et al. v. Teva Pharmaceutical Industries Ltd. et al. (Patent Docs)

TroVax (5T4 vaccine) – US: Settlement announced in TroVax suit – Bavarian Nordic and Oxford BioMedica

Ultram (Tramadol) – US: Patent infringement complaint filed following a Paragraph IV certification: Purdue Pharma Products LP et al. v. Lupin Ltd. et al. (Patent Docs)

Welchol (Colesevelam) – US: Patent infringement complaint filed following a Paragraph IV certification: Daiichi Sankyo Inc. et al. v. Impax Laboratories Inc. (Patent Docs)

Zyrtec (Cetirizine) – France: Tribunale de Grande Instance finds lack of inventive step: Teva Classics SAS, Teva Sante SASU and Teva Pharmaceutical Industries Ltd v. Sepracor Inc (EPLAW)

Zyvox (Linezolid) – US: Patent infringement complaint filed following a Paragraph IV certification: Pfizer Inc. et al. v. Teva Parenteral Medicines Inc. et al. (Patent Docs)